Saber viver com a artrite reumatoide ou a espondilite anquilosante na gravidez
Palavras-chave:
artrite reumatoide, espondilite anquilosante, medicamentos, gravidezResumo
A artrite reumatóide (AR) e a espondilite anquilosante (EA) são doenças que atingem mulheres jovens que vêm a manifestar o
seu desejo de engravidar. O médico deve estar preparado para
responder a todas as perguntas, realçando as vantagens de uma
gravidez planeada. O objectivo primordial, conseguido com a colaboração estreita entre o obstectra e o internista ou reumatologista, é o de manter a doença reumática inactiva, com as drogas mais
seguras para a mãe e para o feto. Nada pode impedir uma mulher
com AR ou EA de ser mãe. De uma forma geral, pode dizer-se que
a gravidez é um período de tolerância imunológica, podendo até
esperar-se uma melhoria destas doenças reumáticas.
Downloads
Referências
Christina D Chambers, Zuehre N Tutuncu, Diana Johnson, Kenneth L Jones: Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Research & Therapy 2006, 8:225.
Christina Chambers, Gideon Koren, Zuhre n Tutuncu, Diana Johnson, Keneth L Jones: Are new agents used to treat rheumatoid arthritis safe to take during pregnancy? Canadian Family Physician 2007; 53: 409-412.
Bonnie L Bermas: Rheumatoid arthritis and pregnancy.www.UpToDate.com2007.
Benjamin Bar Oz, Richard Hackman, Tom Einarson, Gideon Koren: Pregnancy outcome after cyclosporine therapy during pregnancy: A meta-analysis. Transplantation 2001; 71(8): 1051-1055.
Vishal R Tandon, Sudhaa Sharma, Annil Mahajan, Vijay Kahajuria, Ajay Kumar: Pregnancy and Rheumatoid Arthritis. Indian J Med Sci 2006;
(8):334-344.
M Ostensen, L Fuhrer, R Mathieu, MSeitz, P M Villiger: A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004;63:1212-1217.
Namieta M janssen, Marcia S Genta: The effects of immunosupressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 2000; 160: 610-619.
P Saar, W Hermann, U Muller-Ladner:Connective tissue diseases and pregnancy. Rheumatology 2006;45:30-32.
Fokaline Vroom, Hermien Walle, Mart Van de Laar, Jacobus Brouwers, Lolkje Jong-van den Berg: Disease-Modifying Antirheumatic Drugs in Pregnancy. Drug Safety 2006:29(10):845-863.
A J Kinder, J Edwards, A Samanta, F Nichol: Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate. Rheumatology 2004;43:1195-1196.
Bénédicte Lewden,Thierry Vial,Elisabeth Elefant, Agnés Nelva, Patrick Carlier, Jacqes Descotes: Low dose methotrexate in the first trimester of pregnancy: results of a French Collaborative Study. The Journal of Rheumatology
;31(12): 2360-2364.
Monika Ostensen, Helge Hartmann, Kjell Salvesen: Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. The Journal of Rheumatology 2000;27(8): 1872-1875.
Jeffry A Katz, Christian Antoni, Gregory F Keenan, Deirdre E Smith, Stephen J. Jacobs, Gary R Lichtenstein: Outcome of pregnancy in women
receiving infliximab for the treatment of Crohn’s Disease and Rheumatoid Arthritis. Am J Gastroenterol 2004;99:2385-2392.
Chakravarty E F, Sanchez Yamamoto, Bush T M:Disease Modifying antirheumatic drugs in women with Rheumatoid Arthritis of childbearing age:a survey of pratice pattern and frequency outcomes. J Rheumatol 2003;30:241-246.
Josef S Smolen, Daniel Aletaha, Michael H Weisman, Paul Emery: New Therapies for treatment of rheumatoid arthritis.www.thelancet.com Published online June 13, 2007.
Kimby E, Sverrisdottir A, Ellinder G: Safety of rituximab therapy during the first trimester of pregnancy:a case history. Eur J Haematol 2004;72(4):292-295.
Ojeda-Uribe M, Guilliot C, Jung G, Drenou B, Brunot A: Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol 2006;26(4):252-255.
Ficheiros Adicionais
Publicado
Como Citar
Edição
Secção
Licença
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Direitos de Autor (c) 2023 Medicina Interna
Acesso livre
